Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (141-150 of 324) with videos related to

Pageof 33
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
AIDS (London, England)|March 22, 2006
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapyGail V Matthews, Angeline Bartholomeusz, Stephen Locarnini, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
Sexual Health|May 20, 2011
Participants' perspectives of self-collected anal cytological swabsLeon P Botes, Fengyi Jin, Chris Bourne, et al.
AIDS Research and Therapy|March 13, 2012
Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in ThailandAnchalee Avihingsanon, Gail V Matthews, Sharon R Lewin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2007
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfectionMilos Opravil, Joe Sasadeusz, David A Cooper, et al.
AIDS (London, England)|July 1, 2010
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAmit C Achhra, Janaki Amin, Matthew G Law, et al.
The Journal of Infectious Diseases|October 28, 2010
Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapyBenjamin G Oliver, Julian H Elliott, Patricia Price, et al.
Plos One|March 4, 2014
Determinants of suicide and accidental or violent death in the Australian HIV Observational DatabaseHamish McManus, Kathy Petoumenos, Teo Franic, et al.
Human Vaccines|September 25, 2010
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infectionAtchriya Hemachandra, Rebekah L Puls, Sunee Sirivichayakul, et al.
Pageof 33

Showing results (141-150 of 324) with videos related to

Sort By:
Pageof 33
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
AIDS (London, England)|March 22, 2006
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapyGail V Matthews, Angeline Bartholomeusz, Stephen Locarnini, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
Sexual Health|May 20, 2011
Participants' perspectives of self-collected anal cytological swabsLeon P Botes, Fengyi Jin, Chris Bourne, et al.
AIDS Research and Therapy|March 13, 2012
Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in ThailandAnchalee Avihingsanon, Gail V Matthews, Sharon R Lewin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2007
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfectionMilos Opravil, Joe Sasadeusz, David A Cooper, et al.
AIDS (London, England)|July 1, 2010
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAmit C Achhra, Janaki Amin, Matthew G Law, et al.
The Journal of Infectious Diseases|October 28, 2010
Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapyBenjamin G Oliver, Julian H Elliott, Patricia Price, et al.
Plos One|March 4, 2014
Determinants of suicide and accidental or violent death in the Australian HIV Observational DatabaseHamish McManus, Kathy Petoumenos, Teo Franic, et al.
Human Vaccines|September 25, 2010
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infectionAtchriya Hemachandra, Rebekah L Puls, Sunee Sirivichayakul, et al.
Pageof 33